- Home
- FRPH vs VERV Comparison
FRPH vs VERV Comparison
Compare FRPH & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPH
- VERV
- Stock Information
- Founded
- FRPH 1986
- VERV 2018
- Country
- FRPH United States
- VERV United States
- Employees
- FRPH N/A
- VERV N/A
- Industry
- FRPH Real Estate
- VERV Medicinal Chemicals and Botanical Products
- Sector
- FRPH Finance
- VERV Health Care
- Exchange
- FRPH Nasdaq
- VERV Nasdaq
- Market Cap
- FRPH 589.9M
- VERV 475.0M
- IPO Year
- FRPH N/A
- VERV 2021
- Fundamental
- Price
- FRPH $30.75
- VERV $7.28
- Analyst Decision
- FRPH
- VERV Strong Buy
- Analyst Count
- FRPH 0
- VERV 4
- Target Price
- FRPH N/A
- VERV $25.75
- AVG Volume (30 Days)
- FRPH 26.2K
- VERV 1.3M
- Earning Date
- FRPH 03-05-2025
- VERV 02-28-2025
- Dividend Yield
- FRPH N/A
- VERV N/A
- EPS Growth
- FRPH 45.62
- VERV N/A
- EPS
- FRPH 0.40
- VERV N/A
- Revenue
- FRPH $31,414,000.00
- VERV $24,396,000.00
- Revenue This Year
- FRPH N/A
- VERV $106.46
- Revenue Next Year
- FRPH N/A
- VERV N/A
- P/E Ratio
- FRPH $76.89
- VERV N/A
- Revenue Growth
- FRPH 4.04
- VERV 219.91
- 52 Week Low
- FRPH $26.99
- VERV $4.31
- 52 Week High
- FRPH $33.00
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- FRPH 48.40
- VERV 47.08
- Support Level
- FRPH $31.07
- VERV $7.44
- Resistance Level
- FRPH $31.66
- VERV $9.31
- Average True Range (ATR)
- FRPH 0.59
- VERV 0.67
- MACD
- FRPH -0.02
- VERV -0.12
- Stochastic Oscillator
- FRPH 38.02
- VERV 14.01
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.